0001193125-26-211987
SEC filingQ1 revenue declined 12.8% to $8.2M due to collaboration timing as clinical trials progressed toward completion, while operating losses widened 14.4% to $11.4M reflecting ongoing R&D investments in the antiviral pipeline amid no approved products.
Assembly Biosciences reported Q1 2026 results reflecting the biotech's focus on advancing its antiviral pipeline amid persistent operating losses. Revenue of $8.2 million declined 12.8% from $9.4 million in the prior-year quarter, attributable to timing shifts in Gilead collaboration services. This decline underscores progress toward clinical trial completions, as external program costs—tracked by product candidate post-nomination—represent a major portion of R&D expenses.
GAAP operating income deteriorated to -$11.4 million, a 14.4% worsening from -$9.9 million, yielding an operating margin of -138.4%. This reflects the company's significant research and development investments without FDA-approved products to generate sales revenue, a pattern of unprofitability since incorporation in 2005. Net income followed suit at -$9.1 million, up 3.0% in magnitude from -$8.8 million, with diluted EPS of -$0.54 showing 53.8% improvement from -$1.17, likely tied to share count changes.
Cash flow from operations used $22.1 million, an improvement from $23.4 million prior year, aided by vendor payment timing after Phase 1 completions; minimal capital expenditures of $19 thousand were recorded versus none last year. These dynamics highlight operational discipline amid pipeline advancement.
Liquidity remains sufficient to meet operating needs into 2028 under the current plan, supporting R&D continuity despite anticipated expense growth. This positions Assembly Biosciences to pursue pipeline milestones while managing cash burn.